AIM2 and lung cancer: In lung cancer tissues, pDCs have been found to activate the AIM2 inflammasome through type I IFN signaling, conducive to caspase-1 aggregation and the production of IL-1α and IL-10 but not IL-1β and IL-18 indirectly, leading to the immunosuppressive properties of pDCs and thus benefiting tumor progression (80).